Ipratropium bromide - Accord Healthcare Ltd
Accord Healthcare
Description
Antimuscarinic bronchodilator.
Acute bronchospasm by inhalation of nebulised solution
• Child under 5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Severe or life-threatening acute asthma
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Indications
For the management of reversible airway obstructions, particularly in COPD, and rhinitis.
Ipratropium can provide short-term relief in chronic asthma, but short-acting beta2 agonists are preferred as they act more quickly.
The aerosol inhalation of ipratropium can be used for short-term relief in mild COPD in patients who are not using a long-acting antimuscarinic drug. Its maximal effect occurs 30–60 minutes after use. Its duration of action is three to six hours and bronchodilation can usually be maintained with treatment three times a day.
Preparations Available
Nebuliser liquid
Sizes Available
Nebuliser liquid
250 mcg/1 ml, 20 doses
500 mcg/2 ml, 20 doses
More on: Bronchodilators , Antimuscarinic bronchodilators